Investigational drug · Phase 2
ANG003
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ANG003"
First trial start
2026
Apr 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ANG003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis (CF)
Approved drugs for the same conditions: Pancreatic cancer · Cystic fibrosis · Respiratory · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ANG003" as an intervention, largest first.
- Phase 2 Study to Assess the Safety and Efficacy of ANG003Pivotal-lookingRecruiting
Anagram Therapeutics, Inc.Industry
NCT07450547 · 113 participants (planned) · Start Apr 24, 2026 · Primary completion Jul 2027
Drug: ANG003 Dose A; ANG003 Dose B and 1 more · For: Exocrine Pancreatic Insufficiency (EPI); Cystic Fibrosis (CF)
Sites: Long Beach, California; Los Angeles, California; Denver, Colorado · 28 sites in all
Anagram Therapeutics, Inc.Industry
NCT06052293 · 57 participants · Start Aug 25, 2023 · Primary completion Jul 8, 2024
Drug: ANG003 · For: Exocrine Pancreatic Insufficiency
Sites: Little Rock, Arkansas; Long Beach, California; Denver, Colorado · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum to "Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis" [Journal of Cystic Fibrosis Original Article Articles in Press July 31, 2025].
Sathe M, Freedman SD, Putman MS, et al. · J Cyst Fibros 2026
- Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis.
Sathe M, Freedman SD, Putman MS, et al. · J Cyst Fibros 2025
Also in development for Exocrine Pancreatic Insufficiency (EPI)
- NHS7108Phase 21 trial
Aimmune Nestlé Health Science US R&D, LLC · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.